Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2017 Jan 30;16(4):578–590. doi: 10.1158/1535-7163.MCT-16-0606

Figure 3. HJC0152 suppresses proliferation and induces apoptosis in HNSCC cells.

Figure 3

(A) Reduction of clone formation ability in HJC0152-treated SCC25 and CAL27 cells. (B) HJC0152-induced G0/G1 phase arrest of SCC25 and CAL27 cells (P < 0.05). (C) Annexin V/propidium iodide (PI) staining showing that the percentage of apoptotic cells was significantly increased by HJC0152 treatment in a dose-dependent manner. (D) SCC25 and CAL27 cells were treated with HJC0152 for 24 h, and the expression levels of cell cycle- and apoptosis-related proteins were analyzed by Western blotting. (E) Cell viability of SCC25 and CAL27 cell lines were significantly impaired after HJC0152 treatment for 72 hours (Scale bar, 100μm). Cells were treated with HJC0152 or DMSO for 1, 2, 3, 4, 5 day s respectively, and then measured by MTT assay (P < 0.05). * P < 0.05, *** P < 0.001.